Lamin chromatin binding is modulated by interactions of different LAP2α domains with lamins and chromatin.

Cell biology Chromosome organization Molecular interaction Nucleic acids

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
18 Oct 2024
Historique:
received: 02 04 2024
revised: 11 06 2024
accepted: 29 08 2024
medline: 25 9 2024
pubmed: 25 9 2024
entrez: 25 9 2024
Statut: epublish

Résumé

Lamins A and C are components of the lamina at the nuclear periphery and associate with heterochromatin. A distinct, relatively mobile pool of lamin A/C in the nuclear interior associates with euchromatic regions and with lamin-associated polypeptide 2α (LAP2α). Here we show that phosphorylation-dependent impairment of lamin assembly had no effect on its chromatin association, while LAP2α depletion was sufficient to increase chromatin association of lamins. This suggests that complex interactions between LAP2α, chromatin, and lamins regulate lamin chromatin binding. Both the C terminus of LAP2α and its N-terminal LAP2-Emerin-MAN1 (LEM) domain, mediating interaction with lamin A/C indirectly via barrier-to-autointegration factor (BAF), are required for binding to lamins. The N-terminal LEM-like domain of LAP2α, but not its LEM domain, mediates chromatin association of LAP2α and requires LAP2α dimerization via its C terminus. Our data suggest that formation of several LAP2α-, lamin A/C-, and BAF-containing complexes in the nucleoplasm and on chromatin affects lamin chromatin association.

Identifiants

pubmed: 39319273
doi: 10.1016/j.isci.2024.110869
pii: S2589-0042(24)02094-7
pmc: PMC11417337
doi:

Types de publication

Journal Article

Langues

eng

Pagination

110869

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Auteurs

Daria Filipczak (D)

Max Perutz Labs, Vienna Biocenter Campus (VBC), Dr.-Bohr-Gasse 9 / Vienna Biocenter 5, Vienna 1030, Austria.
Medical University of Vienna, Max Perutz Labs, Dr.-Bohr-Gasse 9 / Vienna Biocenter 5, Vienna 1030, Austria.
Vienna BioCenter PhD Program, a Doctoral School of the University of Vienna and the Medical University of Vienna, Vienna A-1030, Austria.

Anna Souchet (A)

Max Perutz Labs, Vienna Biocenter Campus (VBC), Dr.-Bohr-Gasse 9 / Vienna Biocenter 5, Vienna 1030, Austria.
Medical University of Vienna, Max Perutz Labs, Dr.-Bohr-Gasse 9 / Vienna Biocenter 5, Vienna 1030, Austria.

Konstantina Georgiou (K)

Max Perutz Labs, Vienna Biocenter Campus (VBC), Dr.-Bohr-Gasse 9 / Vienna Biocenter 5, Vienna 1030, Austria.
Medical University of Vienna, Max Perutz Labs, Dr.-Bohr-Gasse 9 / Vienna Biocenter 5, Vienna 1030, Austria.
Vienna BioCenter PhD Program, a Doctoral School of the University of Vienna and the Medical University of Vienna, Vienna A-1030, Austria.

Roland Foisner (R)

Max Perutz Labs, Vienna Biocenter Campus (VBC), Dr.-Bohr-Gasse 9 / Vienna Biocenter 5, Vienna 1030, Austria.
Medical University of Vienna, Max Perutz Labs, Dr.-Bohr-Gasse 9 / Vienna Biocenter 5, Vienna 1030, Austria.

Nana Naetar (N)

Max Perutz Labs, Vienna Biocenter Campus (VBC), Dr.-Bohr-Gasse 9 / Vienna Biocenter 5, Vienna 1030, Austria.
Medical University of Vienna, Max Perutz Labs, Dr.-Bohr-Gasse 9 / Vienna Biocenter 5, Vienna 1030, Austria.

Classifications MeSH